Immune thrombocytopenic purpura
ICD-10 D69.3 · ICD-11 3B64.10

ITP in Children Under 18 with Mucosal Bleeding or Reduced Quality of Life

This protocol covers immune thrombocytopenic purpura (ITP) in paediatric patients — children younger than 18 years — who present with non-life-threatening mucosal bleeding and/or a measurable decline in health-related quality of life.

The specific population addressed here is children with immune thrombocytopenia (ITP) whose clinical picture includes non-life-threatening mucosal bleeding and/or diminished health-related quality of life. This age group and symptom profile define the clinical context and drive the structured treatment approach.

Treatment Approach (partial overview)

Second-line escalation for this population includes rituximab as one of the defined options within a structured ordering — the complete regimen, sequencing criteria, and full clinical guidance are available in the protocol.

Instant Access to Structured Evidence-Based Regimens

References

In children with newly diagnosed ITP who have non-life-threatening mucosal bleeding and/or diminished health-related quality of life, the ASH guideline panel suggests corticosteroids rather than intravenous immunoglobulin or anti-D immunoglobulin.

Rituximab

View source ↗